Corresponding Author: Gerald Gartlehner, MD, MPH, RTI International, 3040 E Cornwallis Rd, Research Triangle Park, NC 27709 (ggartlehner@rti.org).
Accepted for Publication: September 19, 2022.
Correction: This article was corrected on March 21, 2023, for incomplete information in a cell in Table 2.
Author Contributions: Dr Gartlehner had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Gartlehner, Patel, Kahwati.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Gartlehner, Rains.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Gartlehner, Patel.
Obtained funding: Kahwati.
Administrative, technical, or material support: Rains.
Supervision: Gartlehner, Kahwati.
Conflict of Interest Disclosures: Dr Reddy reported receiving personal fees from Boston VA Healthcare for part-time clinical work. No other disclosures were reported.
Funding/Support: This project was funded under contract HHSA-75Q80120D00007, Task Order 01, from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, under a contract to support the US Preventive Services Task Force (USPSTF).
Role of the Funder/Sponsor: Investigators worked with USPSTF members and AHRQ staff to develop the scope, analytic framework, and key questions for this review. AHRQ had no role in study selection, quality assessment, or synthesis. AHRQ staff provided project oversight, reviewed the report to ensure that the analysis met methodological standards, and distributed the draft for peer review. Otherwise, AHRQ had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript findings. The opinions expressed in this document are those of the authors and do not reflect the official position of AHRQ or the US Department of Health and Human Services.
Additional Contributions: We gratefully acknowledge the following individuals for their contributions to this project and deeply appreciate their considerable support for and commitment to this work, including AHRQ staff (Howard Tracer, MD; and Tracy Wolff, MD, MPH), RTI International–University of North Carolina Evidence-based Practice Center staff (Carol Woodell, BSPH; Loraine Monroe; Teyonna Downing; Michelle Bogus; Staci Rachman, BA; Sharon Barrell, MA); and Megan Van Noord, MLIS, for literature searches. We also acknowledge the contributions of members of the USPSTF. USPSTF members, peer reviewers, and federal partner reviewers did not receive financial compensation for their contributions.
Additional Information: A draft version of the full evidence report underwent external peer review from 4 content experts (Cynthia Farquhar, MD, MPH, The University of Auckland; JoAnn Manson, MD, MPH, Brigham and Women’s Hospital; Susan Reed, MD, MPH, University of Washington School of Medicine; and Raja Sayegh, MD, Boston University School of Medicine) and 6 federal partner reviewers from the National Institutes of Health and the National Institute of Diabetes and Digestive and Kidney Diseases. Comments from reviewers were presented to the USPSTF during its deliberation of the evidence and were considered in preparing the final evidence review.
Editorial Disclaimer: This evidence report is presented as a document in support of the accompanying USPSTF recommendation statement. It did not undergo additional review after submission to JAMA.
2.Cobin
RH , Goodman
NF ; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause—2017 update.
Endocr Pract. 2017;23(7):869-880. doi:
10.4158/EP171828.PSPubMedGoogle ScholarCrossref 4.Rossouw
JE , Anderson
GL , Prentice
RL ,
et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial.
JAMA. 2002;288(3):321-333. doi:
10.1001/jama.288.3.321PubMedGoogle ScholarCrossref 5.Anderson
GL , Limacher
M , Assaf
AR ,
et al; Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.
JAMA. 2004;291(14):1701-1712. doi:
10.1001/jama.291.14.1701PubMedGoogle ScholarCrossref 7.Grossman
DC , Curry
SJ , Owens
DK ,
et al; US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement.
JAMA. 2017;318(22):2224-2233. doi:
10.1001/jama.2017.18261PubMedGoogle ScholarCrossref 8.Gartlehner
G , Patel
SV , Feltner
C ,
et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force.
JAMA. 2017;318(22):2234-2249. doi:
10.1001/jama.2017.16952PubMedGoogle ScholarCrossref 10.Harlow
SD , Gass
M , Hall
JE ,
et al; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.
Menopause. 2012;19(4):387-395. doi:
10.1097/gme.0b013e31824d8f40PubMedGoogle ScholarCrossref 11.Gartlehner
G , Patel
SV , Reddy
S , Rains
C , Coker-Schwimmer
M , Kahwati
L . Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: An Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 222. Agency for Healthcare Research and Quality; 2022. AHRQ publication 22-05294-EF-1.
14.West
SL , Gartlehner
G , Mansfield
AJ ,
et al. Comparative effectiveness review methods: clinical heterogeneity. AHRQ publication 10-EHC070-EF. Agency for Healthcare Research and Quality. Published 2010. Accessed September 23, 2022.
https://effectivehealthcare.ahrq.gov/ 16.Manson
JE , Chlebowski
RT , Stefanick
ML ,
et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials.
JAMA. 2013;310(13):1353-1368. doi:
10.1001/jama.2013.278040PubMedGoogle ScholarCrossref 18.Chlebowski
RT , Anderson
GL , Aragaki
AK ,
et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials.
JAMA. 2020;324(4):369-380. doi:
10.1001/jama.2020.9482PubMedGoogle ScholarCrossref 19.Manson
JE , Aragaki
AK , Rossouw
JE ,
et al; WHI Investigators. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials.
JAMA. 2017;318(10):927-938. doi:
10.1001/jama.2017.11217PubMedGoogle ScholarCrossref 20.Manson
JE , Aragaki
AK , Bassuk
SS ,
et al; WHI Investigators. Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial.
Ann Intern Med. 2019;171(6):406-414. doi:
10.7326/M19-0274PubMedGoogle ScholarCrossref 22.Prentice
RL , Aragaki
AK , Chlebowski
RT ,
et al. Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50-59 years of age.
Am J Epidemiol. 2021;190(3):365-375. doi:
10.1093/aje/kwaa210PubMedGoogle ScholarCrossref 24.Espeland
MA , Rapp
SR , Manson
JE ,
et al; WHIMSY and WHIMS-ECHO Study Groups. Long-term effects on cognitive trajectories of postmenopausal hormone therapy in two age groups.
J Gerontol A Biol Sci Med Sci. 2017;72(6):838-845. doi:
10.1093/gerona/glw156PubMedGoogle ScholarCrossref 25.Chlebowski
RT , Anderson
GL , Sarto
GE ,
et al. Continuous combined estrogen plus progestin and endometrial cancer: the Women’s Health Initiative randomized trial.
J Natl Cancer Inst. 2015;108(3):djv350. doi:
10.1093/jnci/djv350PubMedGoogle ScholarCrossref 27.Kato
I , Chlebowski
RT , Hou
L ,
et al. Menopausal estrogen therapy and non-Hodgkin’s lymphoma: a post-hoc analysis of Women’s Health Initiative randomized clinical trial.
Int J Cancer. 2016;138(3):604-611. doi:
10.1002/ijc.29819PubMedGoogle ScholarCrossref 28.Watts
NB , Cauley
JA , Jackson
RD ,
et al; Women’s Health Initiative Investigators. No increase in fractures after stopping hormone therapy: results from the Women’s Health Initiative.
J Clin Endocrinol Metab. 2017;102(1):302-308. doi:
10.1210/jc.2016-3270PubMedGoogle ScholarCrossref 30.Liu
L , Klein
L , Eaton
C ,
et al. Menopausal hormone therapy and risks of first hospitalized heart failure and its subtypes during the intervention and extended postintervention follow-up of the Women’s Health Initiative randomized trials.
J Card Fail. 2020;26(1):2-12. doi:
10.1016/j.cardfail.2019.09.006PubMedGoogle ScholarCrossref 32.Prentice
RL , Aragaki
AK , Chlebowski
RT ,
et al. Dual-outcome intention-to-treat analyses in the Women’s Health Initiative randomized controlled hormone therapy trials.
Am J Epidemiol. 2020;189(9):972-981. doi:
10.1093/aje/kwaa033PubMedGoogle ScholarCrossref 33.Mørch
LS , Kjaer
SK , Keiding
N , Løkkegaard
E , Lidegaard
Ø . The influence of hormone therapies on type I and II endometrial cancer: a nationwide cohort study.
Int J Cancer. 2016;138(6):1506-1515. doi:
10.1002/ijc.29878PubMedGoogle ScholarCrossref 34.Park
SY , Wilkens
LR , Kolonel
LN , Henderson
BE , Le Marchand
L . Inverse associations of dietary fiber and menopausal hormone therapy with colorectal cancer risk in the Multiethnic Cohort Study.
Int J Cancer. 2016;139(6):1241-1250. doi:
10.1002/ijc.30172PubMedGoogle ScholarCrossref 35.Bethea
TN , Palmer
JR , Adams-Campbell
LL , Rosenberg
L . A prospective study of reproductive factors and exogenous hormone use in relation to ovarian cancer risk among Black women.
Cancer Causes Control. 2017;28(5):385-391. doi:
10.1007/s10552-016-0840-4PubMedGoogle ScholarCrossref 36.Hsia
J , Criqui
MH , Herrington
DM ,
et al; Women’s Health Initiative Research Group. Conjugated equine estrogens and peripheral arterial disease risk: the Women’s Health Initiative.
Am Heart J. 2006;152(1):170-176. doi:
10.1016/j.ahj.2005.09.005PubMedGoogle ScholarCrossref 38.Tang
JY , Spaunhurst
KM , Chlebowski
RT ,
et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: Women’s Health Initiative randomized trials.
J Natl Cancer Inst. 2011;103(19):1469-1475. doi:
10.1093/jnci/djr333PubMedGoogle ScholarCrossref 44.Waters
DD , Alderman
EL , Hsia
J ,
et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.
JAMA. 2002;288(19):2432-2440. doi:
10.1001/jama.288.19.2432PubMedGoogle ScholarCrossref 51.Anderson
GL , Chlebowski
RT , Aragaki
AK ,
et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial.
Lancet Oncol. 2012;13(5):476-486. doi:
10.1016/S1470-2045(12)70075-XPubMedGoogle ScholarCrossref 52.Anderson
GL , Judd
HL , Kaunitz
AM ,
et al; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial.
JAMA. 2003;290(13):1739-1748. doi:
10.1001/jama.290.13.1739PubMedGoogle ScholarCrossref 54.Brunner
RL , Gass
M , Aragaki
A ,
et al; Women’s Health Initiative Investigators. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women’s Health Initiative randomized clinical trial.
Arch Intern Med. 2005;165(17):1976-1986. doi:
10.1001/archinte.165.17.1976PubMedGoogle ScholarCrossref 55.Cauley
JA , Robbins
J , Chen
Z ,
et al; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial.
JAMA. 2003;290(13):1729-1738. doi:
10.1001/jama.290.13.1729PubMedGoogle ScholarCrossref 57.Chlebowski
RT , Anderson
GL , Manson
JE ,
et al. Lung cancer among postmenopausal women treated with estrogen alone in the women’s health initiative randomized trial.
J Natl Cancer Inst. 2010;102(18):1413-1421. doi:
10.1093/jnci/djq285PubMedGoogle ScholarCrossref 58.Chlebowski
RT , Hendrix
SL , Langer
RD ,
et al; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial.
JAMA. 2003;289(24):3243-3253. doi:
10.1001/jama.289.24.3243PubMedGoogle ScholarCrossref 59.Chlebowski
RT , Schwartz
AG , Wakelee
H ,
et al; Women’s Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial.
Lancet. 2009;374(9697):1243-1251. doi:
10.1016/S0140-6736(09)61526-9PubMedGoogle ScholarCrossref 60.Chlebowski
RT , Wactawski-Wende
J , Ritenbaugh
C ,
et al; Women’s Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women.
N Engl J Med. 2004;350(10):991-1004. doi:
10.1056/NEJMoa032071PubMedGoogle ScholarCrossref 61.Culhane
NS . Estrogen plus progestin may increase incidence of dementia.
J Fam Pract. 2003;52(10):754-755.
PubMedGoogle Scholar 64.Espeland
MA , Brunner
RL , Hogan
PE ,
et al; Women’s Health Initiative Study of Cognitive Aging Study Group. Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women’s Health Initiative Study of Cognitive Aging extension.
J Am Geriatr Soc. 2010;58(7):1263-1271. doi:
10.1111/j.1532-5415.2010.02953.xPubMedGoogle ScholarCrossref 65.Espeland
MA , Rapp
SR , Shumaker
SA ,
et al; Women’s Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study.
JAMA. 2004;291(24):2959-2968. doi:
10.1001/jama.291.24.2959PubMedGoogle ScholarCrossref 70.Vickers
MR , Martin
J , Meade
TW ; WISDOM Study Team. The Women’s International Study of long-Duration Oestrogen after Menopause (WISDOM): a randomised controlled trial.
BMC Womens Health. 2007;7(2):2. doi:
10.1186/1472-6874-7-2PubMedGoogle ScholarCrossref 71.Wassertheil-Smoller
S , Hendrix
SL , Limacher
M ,
et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial.
JAMA. 2003;289(20):2673-2684. doi:
10.1001/jama.289.20.2673PubMedGoogle ScholarCrossref 74.Shumaker
SA , Legault
C , Rapp
SR ,
et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial.
JAMA. 2003;289(20):2651-2662. doi:
10.1001/jama.289.20.2651PubMedGoogle ScholarCrossref 75.Shumaker
SA , Legault
C , Kuller
L ,
et al; Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study.
JAMA. 2004;291(24):2947-2958. doi:
10.1001/jama.291.24.2947PubMedGoogle ScholarCrossref 76.Rossouw
JE , Prentice
RL , Manson
JE ,
et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. [Published corection appears in
JAMA. 2008;299(12):1426].
JAMA. 2007;297(13):1465-1477. doi:
10.1001/jama.297.13.1465PubMedGoogle ScholarCrossref 77.Ritenbaugh
C , Stanford
JL , Wu
L ,
et al; Women’s Health Initiative Investigators. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women’s Health Initiative randomized clinical trial.
Cancer Epidemiol Biomarkers Prev. 2008;17(10):2609-2618. doi:
10.1158/1055-9965.EPI-08-0385PubMedGoogle ScholarCrossref 78.Resnick
SM , Maki
PM , Rapp
SR ,
et al; Women’s Health Initiative Study of Cognitive Aging Investigators. Effects of combination estrogen plus progestin hormone treatment on cognition and affect.
J Clin Endocrinol Metab. 2006;91(5):1802-1810. doi:
10.1210/jc.2005-2097PubMedGoogle ScholarCrossref 79.Resnick
SM , Espeland
MA , An
Y ,
et al; Women’s Health Initiative Study of Cognitive Aging Investigators. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy.
J Clin Endocrinol Metab. 2009;94(11):4152-4161. doi:
10.1210/jc.2009-1340PubMedGoogle ScholarCrossref 80.Rapp
SR , Espeland
MA , Shumaker
SA ,
et al; WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial.
JAMA. 2003;289(20):2663-2672. doi:
10.1001/jama.289.20.2663PubMedGoogle ScholarCrossref 82.Hulley
S , Grady
D , Bush
T ,
et al; Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
JAMA. 1998;280(7):605-613. doi:
10.1001/jama.280.7.605PubMedGoogle ScholarCrossref 84.Hendrix
SL . The Women’s Health Initiative estrogen plus progestin trial: the study and how it changes our practice.
J Am Osteopath Assoc. 2003;103(2)(suppl 2):S3-S5.
PubMedGoogle Scholar 86.Margolis
KL , Bonds
DE , Rodabough
RJ ,
et al; Women’s Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial.
Diabetologia. 2004;47(7):1175-1187. doi:
10.1007/s00125-004-1448-xPubMedGoogle ScholarCrossref 88.Kanaya
AM , Herrington
D , Vittinghoff
E ,
et al; Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial.
Ann Intern Med. 2003;138(1):1-9. doi:
10.7326/0003-4819-138-1-200301070-00005PubMedGoogle ScholarCrossref 89.Hulley
S , Furberg
C , Barrett-Connor
E ,
et al; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
JAMA. 2002;288(1):58-66. doi:
10.1001/jama.288.1.58PubMedGoogle ScholarCrossref 94.LaCroix
AZ , Chlebowski
RT , Manson
JE ,
et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.
JAMA. 2011;305(13):1305-1314. doi:
10.1001/jama.2011.382PubMedGoogle ScholarCrossref 95.Resnick
SM , Coker
LH , Maki
PM , Rapp
SR , Espeland
MA , Shumaker
SA . The Women’s Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline.
Clin Trials. 2004;1(5):440-450. doi:
10.1191/1740774504cn040oaPubMedGoogle ScholarCrossref 96.Vickers
MR , MacLennan
AH , Lawton
B ,
et al; WISDOM Group. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.
BMJ. 2007;335(7613):239. doi:
10.1136/bmj.39266.425069.ADPubMedGoogle ScholarCrossref 97.Gleason
CE , Dowling
NM , Wharton
W ,
et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study.
PLoS Med. 2015;12(6):e1001833. doi:
10.1371/journal.pmed.1001833PubMedGoogle ScholarCrossref 98.Chlebowski
RT , Rohan
TE , Manson
JE ,
et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women’s health initiative randomized clinical trials.
JAMA Oncol. 2015;1(3):296-305. doi:
10.1001/jamaoncol.2015.0494PubMedGoogle ScholarCrossref 99.Canonico
M , Plu-Bureau
G , O’Sullivan
MJ ,
et al. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women’s Health Initiative hormone therapy clinical trials.
Menopause. 2014;21(3):214-220. doi:
10.1097/GME.0b013e31829752e0PubMedGoogle ScholarCrossref 100.Cherry
N , McNamee
R , Heagerty
A , Kitchener
H , Hannaford
P . Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial.
BJOG. 2014;121(6):700-705. doi:
10.1111/1471-0528.12598PubMedGoogle ScholarCrossref 102.Rimoin
LP , Kwatra
SG , Yosipovitch
G . Female-specific pruritus from childhood to postmenopause: clinical features, hormonal factors, and treatment considerations.
Dermatol Ther. 2013;26(2):157-167. doi:
10.1111/dth.12034PubMedGoogle ScholarCrossref